型号:
产品价格:电议      采购度:1606      原产地:美洲
发布时间:2021/7/24 0:44:57 所属地区:上海 上海市
简要描述:
Plerixafor octahydrochloride (AMD3100 octahydrochloride) 是一种选择性的 CXCR4 拮抗剂, IC50 为 44 nM。
标签:Mozobil
产品详情
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 155148-31-5
MCE 站:Plerixafor octahydrochloride
产品活性:Plerixafor octahydrochloride (AMD3100 octahydrochloride) 是一种选择性的 CXCR4 拮抗剂, IC50 为 44 nM。
研究领域:GPCR/G Protein | Immunology/Inflammation | Anti-infection
作用靶点:CXCR | HIV | Virus Protease
In Vitro: The CXCR4 inhibitor Plerixafor (AMD3100) is a potent inhibitor of CXCL12-mediated chemotaxis (IC50, 5.7 nM) with a potency slightly better than its affinity for CXCR4. Treating the cells with CCX771 or CXCL11 has no effect on CXCL12-mediated MOLT-4 or U937 TEM. In contrast, 10 μM Plerixafor inhibits CXCL12-mediated TEM in both cells lines. Plerixafor (10 μM)-treated cells show a moderate reduction in cell proliferation compared to CXCL12-stimulated cells, which do not reach statistical significance.
In Vivo: Plerixafor (2 mg/kg) administration to UUO mice exacerbates renal interstitial T cell infiltration, resulting in increased production of the pro-inflammatory cytokines IL-6 and IFN-γ and decreased expression of the anti-inflammatory cytokine IL-10. Both perivascular and interstitial fibrosis are significantly reduced by the CXCR4 antagonist, Plerixafor (AMD3100) at 8 weeks. LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | Small Molecule Immuno-Oncology Compound Library | Peptidomimetic Library | Drug Repurposing Compound Library | Diabetes Related Compound Library | Endocrinology Compound Library | Anti-COVID-19 Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Doxorubicin hydrochloride | Chloroquine | 5-Fluorouracil | 4-Phenylbutyric acid | Valproic acid | (-)-Epigallocatechin Gallate | Shikonin | Glycyrrhizic acid | Ivermectin | Aspirin | Ebselen | Dynasore | Kaempferol | Flavopiridol | Maraviroc | Hydroxyurea | Dimethyl fumarate | SB225002 | Artesunate | Baicalin | Probenecid | Ritonavir | Fasudil Hydrochloride | Lopinavir | Betulinic acid | Lamivudine | Reparixin | Rolipram
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:14:29
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品